Prospective Evaluation of Confirmatory Testing for Primary Aldosteronism

CompletedOBSERVATIONAL
Enrollment

183

Participants

Timeline

Start Date

January 15, 2017

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Primary Aldosteronism
Interventions
DIAGNOSTIC_TEST

Seated intravenous saline infusion test

"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."

DIAGNOSTIC_TEST

Ultra low-dose ACTH stimulation test

"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."

Trial Locations (1)

Unknown

University of Calgary, Calgary

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Hypertension Canada

OTHER

lead

University of Calgary

OTHER

NCT04422756 - Prospective Evaluation of Confirmatory Testing for Primary Aldosteronism | Biotech Hunter | Biotech Hunter